Определение полисорбата 80 в биофармацевтических препаратах с помощью оптимизированной колориметрической методики by A. Seregin S. et al.
АНАЛИТИЧЕСКИЕ МЕТОДЫ 
В ХИМИИ И ХИМИЧЕСКОЙ ТЕХНОЛОГИИ
ANALYTICAL METHODS IN CHEMISTRY 
AND CHEMICAL TECHNOLOGY
Quantification of polysorbate 80 in biopharmaceutical 
formulations implementing an optimized colorimetric approach
Aleksandr S. Seregin1, Natalya V. Orlova1, Aleksandr D. Askretkov2,@, 
Dmitry I. Zybin2, Yuri A. Seregin1
1Scientific Center “Kurchatov Institute,” Research Institute for Genetics and Selection of Industrial 
Microorganisms, Moscow, 117545 Russia
2PHARMAPARK, Moscow, 117246 Russia
@Автор для переписки, e-mail: askretkov.a.d@gmail.com
Objectives. We hereby describe an improvement of a previously developed quantification 
technique for polysorbate 80 in biopharmaceutical formulations (darbepoetin alfa and eculizumab) 
and report the validation of the new approach.
Methods. Polysorbate was isolated from analyte samples by protein precipitation using an 
organic solvent, followed by supernatant evaporation in vacuum. Polysorbate was derivatized 
using a ferric thiocyanate reagent and extracted into an organic phase; the relevant optical 
density measurements were performed.
Results. We established the optimal conditions for each step of the analysis procedure. The 
accuracy was 97–102% in the tested analytical range, the relative standard deviation did not 
exceed 5%, and the limit of quantification was 0.01 mg/mL.
Conclusions. The reported approach is highly sensitive; polysorbate isolation and quantification 
do not depend on the matrix or, most importantly, the protein.
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Цели. В данной работе была усовершенствована ранее разработанная методика 
определения полисорбата 80 в биотехнологических препаратах (дарбэпоэтин альфа, 
экулизумаб), а также проведена ее валидация.
Методы. Полисорбат извлекали из пробы осаждением белка органическим растворите-
лем, затем выпаривали супернатант в вакууме. Полисорбат дериватизировали опти-
мизированным железо–тиоцианатным реагентом; дериват экстрагировали в слой орга-
нического растворителя и измеряли оптическую плотность.
Результаты. Были установлены оптимальные условия для каждой стадии методи-
ки. Правильность находится в диапазоне степени извлечения 97–102%, относительное 
стандартное отклонение составляет не более 5%, предел количественного определения 
методики 0.01 мг/мл.
Выводы. Представленная методика имеет высокую чувствительность. Извлечение и 
определение полисорбата не зависят от матрикса пробы – прежде всего, от присутству-
ющего белка.
Ключевые слова: валидация, дарбэпоэтин альфа, экулизумаб, полисорбат, осаждение, 
тиоцианат железа.
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INTRODUCTION
Polysorbates (PSs), especially polysorbate 20 (PS20) 
and polysorbate 80 (PS80), are very common surfactants 
in biopharmaceutical formulations, due to their low 
toxicity, reasonably low cost, and high efficacy at low 
concentrations. The addition of PSs to biopharmaceuticals 
affords a mitigation of protein adsorption, denaturation, 
degradation [2], and aggregation [3, 4] that may occur 
in stress conditions, such as agitation [5], freeze–thaw 
cycling [6], and contact with an air–water interface in 
the course of downstream purification and storage [7]. In 
the course of biopharmaceutical downstream production 
and storage, PS concentration can significantly change 
because they tend to be adsorbed onto surfaces and 
filter membranes, so the target PS concentration, which 
ensures protein stability, in intermediate downstream 
products, drug substances, and drug dosage forms 
must always be maintained. Therefore, in this context, 
access to a simple and relatively fast method for PS 
quantification is a necessity.
PSs are characterized by heterogeneous structures, a 
lack of chromophoric groups, and a low tendency to bind 
proteins [8, 9], so PS analysis is not a very straightforward 
proposition. Numerous analytical methods have 
been developed, including high-performance liquid 
chromatography relying on spectrophotometry [10, 11], 
mass-spectrometry [12], evaporative light scattering 
[9], fluorometry [13], or gas chromatography [14] for 
analyte detection. In these approaches, laborious and 
time-consuming sample pre-treatment procedures, such 
as alkaline or acidic hydrolysis, solid-phase extraction, 
and protein removal, are usually required to obtain 
reliable analytical results. Notably, complex sample pre-
treatment procedures represent a challenge also from the 
standpoint of possible mistakes in experiment execution.
Since PSs are, in fact, a group of closely 
related molecules lacking a well-defined structure, 
their properties and chemical composition may 
differ substantially from batch to batch. Therefore, 
quantification methods that detect only some PS 
components—e.g., oleic [10–12] or lauric acid, total 
fatty acid content [9, 13], or ethylene glycol released 
through hydrolysis [14]—often provide imprecise data. 
Conversely, the results of detection methods that rely 
on the ability of PSs to form micelles are not affected 
by PS batch-to-batch variability or even by the use of 
PS samples supplied by different manufacturers. A 
commonly used analytical approach is colorimetry, 
which is based on the formation of complexes between 
PSs and iron, cobalt, or molybdenum thiocyanates 
[15, 16], followed by extraction of the said complexes 
into an organic solvent. Exploitation of the formation 
of a polysorbate–iodine–starch complex has also 
been suggested for PS quantification [17]. Another 
possible analytical technique is based on the inclusion 
of a fluorescent dye into PS micelles, followed by 
fluorescence detection and quantitation [18, 19].
The aim of this work was to develop an optimized 
spectrophotometric method for PS quantification that 
relies on PS reactivity with ferric thiocyanate, so as to 
improve the previously described technique [1]. We also 
report the validation of PS80 analysis in the presence of 
darbepoetin alfa and eculizumab, the drugs that appeared 
to interfere with the results of the analysis performed 
with the previously developed approach [1].
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MATERIALS AND METHODS
Chemicals and reagents
All reagents (analytical grade) were purchased 
from Sigma-Aldrich, USA. Biopharmaceuticals were 
drug substance solutions (or active pharmaceutical 
ingredients) of darbepoetin alfa and eculizumab, both 
manufactured by PHARMAPARK, Russia.
Assay procedure
The eculizumab drug substance, normally 
containing a PS80 concentration of 0.02%, was diluted 
five-fold before analysis. Conversely, the darbepoetin 
alfa drug substance, containing 0.005% PS80, was 
analyzed without dilution.
In detail, 1000 µL of acetone was added to 400 µL 
of standard (0.002–0.008% PS80 solutions in ddH2O) 
and sample solutions. The contents were briefly mixed 
and centrifuged at 10000 rpm for 10 min in a 5417C 
centrifuge (Eppendorf, Germany). Subsequently, 1000 µL 
of each supernatant was placed in a fresh tube and the 
solvent removed by evaporation on a vacuum rotary 
evaporator RVC2-18HCL (Martin-Christ, Germany) for 
2 h at 25°C. The dried samples were dissolved in 100 µL 
of 2 M sodium chloride. To the obtained solutions were 
then added 400 µL of freshly prepared derivatization 
reagent, which consists of equal volumes of 1 M iron(III) 
chloride and 6.4 M ammonium thiocyanate. Finally, 500 µL 
of dichloromethane (kept at −20°C) were added, and the 
capped tubes were vigorously shaken for 5 min using a 
Bullet Blender BBX24 (Biostep, Germany). The tubes 
were then subjected to centrifugation at 10000 rpm for 
10 min at room temperature. The optical density (OD) of 
the lower phase (the organic solvent layer) was measured 
at 510 nm on an Ultrospec 7000 instrument (General 
Electric, USA) against a blank consisting of deionized 
water. The concentrations of PS80 were determined by 
linear regression using a calibration curve obtained with 
the standard samples.
Validation
All validation procedures were carried out 
in accordance with the State Pharmacopeia of the 
Russian Federation (14th edition) and the ICH Q2(R1) 
guidelines. Specificity, linearity, analytical range, 
precision, accuracy, limit of detection (LOD), and limit 
of quantification (LOQ) were all evaluated.
RESULTS AND DISCUSSION
Specificity
To evaluate the analytical technique’s specificity, 
we used pre-formulated PS-free protein substances of 
darbepoetin alfa and eculizumab that were characterized 
by concentrations of 2.1 and 15.1 mg/mL, respectively. 
The values of the optical density of these solutions, 
ODmatrix, were compared with the OD of the PS80 standard 
solution at the LOQ (ODLOQ), 0.01 mg/mL. The matrix 
interference (MI) index can be used to quantitatively 
appreciate interference from sample matrix on method 
specificity. MI was calculated by the following equation:
For darbepoetin alfa, the MI was 12.9%, and for 
eculizumab it was 15.1%. Both values did not exceed the 
MI limit of 20% [15].
Linearity
The relationship between the OD and PS80 
concentration was evaluated for five PS80 concentrations 
in the 0.02–0.08 mg/mL range—each in triplicate. The 
calibration curve thus obtained is reported in Fig. 1a, 
and the residuals’ plot (the plot of the deviation of the 
actual data points from the regression line) is reported 
in Fig. 1b.
а b
Fig. 1. Regression of the optical density vs. the concentration of polysorboate 80 (a).
Residual values of the optical density plotted against polysorbate 80 concentration (b).
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As can be evinced from Fig. 1a, the value for the 
correlation coefficient R2 of the regression of the OD vs. 
PS80 concentration is 0.9966. Based on this high value 
and the fact that the residual values (reported in Fig. 1b) 
do not depend on PS80 concentration, we conclude that 
the method meets the linearity criterion.
Accuracy
For the estimation of the method’s accuracy, 
darbepoetin alfa and eculizumab solutions, initially 
PS80-free, were spiked with PS80 to reach the final 
concentration of 0.02, 0.05, and 0.08 mg/mL, in 
the case of darbepoetin alfa, and 0.08, 0.20, and 
0.36 mg/mL, in the case of eculizumab. After PS80 
quantification (as described), the recovery rate at every 
concentration was calculated. In the case of darbepoetin 
alfa, the recovery rate remained in the 98–102% range 
for all concentrations; in the case of eculizumab, the 
corresponding range was 97–100% (Table 1). The 
recovery results for both drug substances were thus 
narrowly scattered around the 100% value, and no 
sample exceeded the recovery range limit of 85–115%; 
within this range, the values are considered to be free 
of systematic error and provide true PS80 concentration 
for the tested samples).
Repeatability and precision
The analytical technique’s repeatability was 
assessed using the data of the linear regression (n = 3). 
The relative standard deviation (RSD) was calculated 
for each concentration. Since protein precipitation 
could affect PS80 extraction and alter analysis 
results, commercial samples of darbepoetin alfa and 
eculizumab (already containing 0.05 and 0.2 mg/mL 
PS80, respectively) were also analyzed (n = 6). For 
the evaluation of the intermediate precision, the same 
analyses were conducted in two additional replicates, 
and the RSD values of overall PS80 concentrations for 
each sample were compared. The relevant data are listed 
in Table 2. In the case of no sample, the repeatability 
limit of 5% or intermediate precision limit of 8% was 
exceeded.
LOD and limit of quantification
The LOD and LOQ values were determined using 
the standard deviation of the response, and the slope 
of the calibration plot. The LOQ was determined to be 
0.010 mg/mL and the LOD 0.003 mg/mL.
Robustness
In order to evaluate the analytical method’s 
robustness, we analyzed the effect of varying the 
following parameters (the usual value is shown in bold):
–evaporation temperature (25, 30, and 35°C);
–derivatization time (2, 5, 10, and 20 min).
Standard solutions of PS80, as well as darbepoetin 
alfa and eculizumab drug substances spiked with 
PS80, were analyzed. The recovery of eculizumab and 
darbepoetin alfa was used as robustness criterion. One 
should expect PS80 concentration differences of no 
greater than 8% compared with the results obtained 
using standard procedure.
Table 1. Accuracy estimation
Product Theoretical polysorbate 80 concentration, mg/mL
Obtained polysorbate 80 
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Table 2. Repeatability and intermediate precision
Sample RSD of repeatability, % RSD of intermediate precision, %
PS80, mg/mL
0.020 2.6 (n = 3) 2.7
0.035 3.4 (n = 3) 3.1
0.050 1.6 (n = 3) 1.8
0.065 1.2 (n = 3) 2.0
0.080 1.4 (n = 3) 2.1
Darbepoetin alfa, 2.1 mg/mL 2.5 (n = 6) 3.4
Eculizumab, 16.2 mg/mL 4.6 (n = 6) 5.2
Note: PS80: polysorbate 80; RSD: relative standard deviation.
When the evaporation temperature was elevated 
to 35℃, no effect was observed on the recovery of 
darbepoetin alfa and eculizumab. However, the recovery 
RSD value increased two-fold at this temperature with 
respect to the 25°C case, which could be explained by an 
increased rate of evaporation, splashing, and/or partial 
loss of the sample. Changes in the derivatization time 
did not have much impact on the recovery of the drug 
formulations either. Notably, implementation of a 2-min 
derivatization resulted in a decrease of the samples’ OD.
Subsequently, the stability of the polysorbate–iron 
thiocyanate complex was monitored for 1 h. The PS80 
standard and darbepoetin alfa drug substance samples 
spiked with PS80 (at 0.02, 0.05, and 0.08 mg/mL final 
concentrations) were analyzed at five time points: 10, 
20, 30, 40, and 60 min. Between measurements, the 
solutions were stored in polypropylene tubes at room 
temperature. In Fig. 2 is reported the graph whereby the 
OD is plotted against the incubation time. The OD values 
did not differ from the initial value by more than 8% over 
the 1-h period, for any sample.
Fig. 2. Effect of incubation time on the optical density 
of polysorbate 80 (PS80) standards at different 
concentrations and darbepoetin alfa drug substance 
samples spiked with PS80 to the specified final 
concentrations (DEPO).
Analytical range
We have established the linearity, accuracy, and 
precision of our technique to determine the concentration 
of PS80 in the 0.02–0.08 mg/mL range. Therefore, 
evidence indicates that the PS80 analytical range is 
0.02–0.08 mg/mL when darbepoetin alfa is present. 
However, we need to note that eculizumab was diluted 
five-fold before analysis in all experiments; therefore, in 
this case the PS80 analytical range is 0.1–0.4 mg/mL.
Selection of the derivatization reagent
PS80 is able to form colored complexes with 
thiocyanates of transition metals, especially iron(III), 
molybdenum(V), and cobalt(II). Notably, PS80–metal 
thiocyanate complexes are soluble in organic solvents 
[16]. In non-polar organic solvents, furthermore, all 
these complexes display absorbance peaks in the UV-Vis 
spectrum. The PS80–cobalt(II) thiocyanate complex 
displays two UV-Vis peaks, at 320 nm (higher intensity) 
and 620 nm; PS80–molybdenum(V) thiocyanate 
displays two peaks, at 323 and 475 nm; and PS80–
iron(III) thiocyanate displays one peak at 510 nm. The 
extinction coefficients of the peaks just listed decrease 
in the following order: Fe (510 nm) > Co (320 nm) 
> Mo (323 nm) ≈ Mo (475 nm) > Co (620 nm). As we 
previously discussed [1], the most useful complex from 
the standpoint of our analysis is iron(III) thiocyanate 
because its detection relies on a relatively long 
wavelength; it interferes minimally with the background, 
sample matrix, and the presence of UV-absorbing 
impurities in reagents, and it is characterized by the 
highest sensitivity among the tested metal thiocyanates.
A considerable issue associated with PS80 
derivatization is the high volatility of dichloromethane, 
which could result in quantification errors and increased 
RSD values. Attempts to replace dichloromethane with 
polar organic solvents (e.g., ethyl acetate, butyl acetate, 
or their mixtures with acetonitrile) have failed due to 
the intense color and almost opaque appearance of the 
organic layer, even in the case of blank samples, which 
is caused by the high solubility of the complexes in 
these solvents. However, the use of non-polar organic 
solvents, such as chloroform, carbon tetrachloride, 
toluene, and benzene, yielded similar results to those 
obtained using dichloromethane, although analyte 
sensitivity was 2–4 times lower in all these solvents than 
in dichloromethane. Moreover, collecting the toluene 
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and benzene layers proved difficult, since these solvents’ 
densities were lower than that of the aqueous layer. In 
order to minimize dichloromethane volatility, we cooled 
the metal thiocyanate complex solutions to −20°C before 
adding them to the PS80-containing solutions.
Cuvette fouling
The measurements of the OD were carried 
out in quartz cuvettes. The cuvettes’ surfaces were 
noticeably stained after 3–4 measurements. In order 
to lessen cuvette fouling and maintain the stability of 
the colored complexes, we added 10% sulfuric acid to 
the derivatization reagent [16]. In our previous report 
[1], we recommended rinsing the cuvettes with 96% 
ethanol and dichloromethane after each measurement, 
although complete stain removal was not achieved 
by this approach. In the present study, we revised the 
composition of the derivatization reagent.
According to some sources [20, 21], sodium and 
potassium ions stabilize polyoxyethylene complexes with 
iron(III) thiocyanate. To investigate the effect of such 
ions on PS-based complexes, we added either sodium or 
potassium chloride into the derivatization reagent to the 
final concentrations of 0.1, 0.4, 1.0, and 2.0 M. To estimate 
the stability of the complexes in quartz cuvettes, the 
absorbance of derivatized 0.4 mg/mL PS80 samples was 
determined in six replicates for all sodium and potassium 
chloride ion concentrations. When a derivatization 
reagent containing at least a 0.4 M concentration of 
either sodium or potassium was utilized, the cuvette was 
observed to be much cleaner than in the case whereby the 
derivatization reagent contained no sodium/potassium 
ions or a 0.1 M concentration of them. We conclude that 
the addition of 0.4 M sodium chloride (or potassium 
chloride) is useful for preventing cuvette fouling.
Removal of proteins from PS solutions
Our previous attempt to quantify PS80 in darbepoetin 
alfa and eculizumab formulations using solid-phase 
extraction [1] produced ambiguous results, due to PS80 
adsorption onto the proteins. Performing a preliminary 
protein denaturation with chaotropic agents, such as 
guanidine hydrochloride or urea, partially addressed the 
problem. In this study, we observed no interaction between 
the precipitated protein and PS80 in organic solvent–
water mixtures. To investigate this issue further, we used 
different organic solvents to precipitate the protein, while 
causing no PS80 loss. Darbepoetin alfa, being a highly 
sialylated protein, was difficult to precipitate, and only 
the use of a mixed water–organic solvent with at least 
50% acetone content afforded the complete removal of 
the protein from solution. Eculizumab precipitation was 
carried out in the same manner, and the recovery rate was 
quite similar, close to 100% (see Accuracy subsection in 
RESULTS AND DISCUSSION section).
CONCLUSIONS
The reported spectrophotometric method based 
on ferric thiocyanate complexation was suitable for 
PS quantification in biopharmaceutical formulations in 
the PS concentration range of 0.02–0.08 mg/mL. PS 
extraction was achieved by protein precipitation using 
an organic solvent, followed by supernatant evaporation 
in vacuum. PS was derivatized using an optimized, 
stable ferric thiocyanate reagent, and the derivative 
was extracted into dichloromethane to conduct OD 
measurements.
The optimal conditions for each step of the analysis 
were identified. The accuracy of the technique in the 
mentioned analytical range was 97–102%; the RSD 
of the repeatability did not exceed 5%; the LOQ value 
was 0.01 mg/mL. The approach was validated for PS80 
quantification in darbepoetin alpha and eculizumab drug 
substances. The proposed method was more sensitive 
and precise than the previously reported technique [1], 
and we did not detect any MI.
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